With the growing number of therapies being tested in chronic lymphocytic leukemia (CLL) comes the growing challenge of identifying for each patient which therapies are the best. In this competitive renewal proposal, we propose strategies to identify therapeutic opportunities in individual CLL tumors. A key element of this approach is the ability to predict patient response to individual therapies. We apply many of the basic lessons we have learned in the initial grant period about control of apoptosis, and make use of a tool that we refined in that proposal, BH3 profiling. Building on our prior work in which we found we can correlate in vitro sensitivity to ABT-737 to BH3 profiling results, we propose to test our ability to predict clinical response to the related BCL-2 antagonist, ABT-199 in CLL (Specific Aim #1). In addition, in Specific Aim #2, we propose to identify pathway addiction in individual cases of CLL. In the past, inefficiency of siRNA and shRNA approaches and difficulty of ex vivo culture in CLL have made this issue difficult to address by conventional means. We propose a study using small molecule pathway inhibitors instead of knockdown strategies to evade RNA transfection difficulties. Importantly, we use BH3 profiling to measure early apoptotic signaling within 4-24 of drug treatment, obviating the need for extended ex vivo culture.
Our aim i s to link early apoptotic signaling in response to small molecule inhibitors to pathway addiction. An important advantage of this approach is that detection of apoptotic signaling in primary CLL in response to drugs provides a rational path to clinical translation. Finally, in Specific Aim #3, we propose to investigate how stromal interactions inhibit apoptotic signaling in CLL cells. Moreover, using in vitro co-culture systems, we will study the efficacy and mechanisms of drugs intended to interrupt CLL interactions with stromal cells. Our goal is to identify which CLL patients will most benefit from such therapies.

Public Health Relevance

There is a growing number of new and exciting targeted therapies being tested for treating chronic lymphocytic leukemia and other leukemias. However, it is often difficult to predict which patients will benefit most from these therapies, so that thee is a risk of many being treated with drugs that are not useful, and others not getting drugs from which they could benefit. In this proposal, we test a novel strategy, based on our improved understanding of cell death pathways, for matching individual tumors with the drugs that will work best against them to better personalize therapy for chronic lymphocytic leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA129974-07
Application #
8542772
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Jessup, John M
Project Start
2007-09-26
Project End
2017-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
7
Fiscal Year
2013
Total Cost
$296,244
Indirect Cost
$126,962
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Chonghaile, Triona Ni; Roderick, Justine E; Glenfield, Cian et al. (2014) Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov 4:1074-87
Pan, Rongqing; Hogdal, Leah J; Benito, Juliana M et al. (2014) Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4:362-75
Hogdal, Leah J; Letai, Anthony (2013) BCL-2 inhibition: stemming the tide of myeloid malignancies. Cell Stem Cell 12:269-70
Davids, Matthew S; Letai, Anthony (2013) ABT-199: taking dead aim at BCL-2. Cancer Cell 23:139-41
Del Gaizo Moore, Victoria; Letai, Anthony (2013) BH3 profiling - Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 332:202-5
Sarosiek, Kristopher A; Chi, Xiaoke; Bachman, John A et al. (2013) BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell 51:751-65
Etchin, Julia; Sanda, Takaomi; Mansour, Marc R et al. (2013) KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 161:117-27
Ni Chonghaile, Triona; Sarosiek, Kristopher A; Vo, Thanh-Trang et al. (2011) Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334:1129-33
Yecies, Derek; Carlson, Nicole E; Deng, Jing et al. (2010) Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115:3304-13
Ryan, Jeremy A; Brunelle, Joslyn K; Letai, Anthony (2010) Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci U S A 107:12895-900

Showing the most recent 10 out of 14 publications